StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO)

Analysts at StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a report issued on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Mkm cut their price objective on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, September 23rd.

Aptevo Therapeutics Trading Down 3.5 %

Shares of APVO stock opened at $0.27 on Wednesday. The firm has a fifty day moving average price of $0.25 and a 200 day moving average price of $0.48. Aptevo Therapeutics has a 12 month low of $0.14 and a 12 month high of $13.60.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.67) EPS for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.26. On average, sell-side analysts expect that Aptevo Therapeutics will post -2.97 earnings per share for the current year.

Hedge Funds Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC bought a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.